Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-assisted ISI and aqueous cytokine analysis of Conbercept in retinal vein occlusion
ChiCTR2500109373Phase 4Not yet recruiting
- Sponsor
- Xuzhou No. 1 People's Hospital
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO) and Vein occlusion (RVO) (2 arms), sponsored by Xuzhou No. 1 People's Hospital. Primary endpoints: Ultra-wide-angle FFA ISI in different retinal partitions at baseline, Visual function at baseline and 1 month after 3 Conbercept injections and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
central retinal vein occlusion (CRVO)branch retinal vein occlusion (BRVO)Vein occlusion (RVO)
Beyond the preview
Go deeper on ChiCTR2500109373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109373.